4.7 Article

Single-Nucleotide Polymorphisms in Human NPC1 Influence Filovirus Entry Into Cells

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 218, Issue -, Pages S397-S402

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy248

Keywords

Ebolavirus; Marburgvirus; Niemann-Pick C1 (NPC1); single-nucleotide polymorphism (SNP); NPC1-knockout Vero E6 (Vero E6; NPC1-KO)

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology [16J04404, 16H02627, 15H01249]
  2. National Institute of Allergy and Infectious Diseases, National Institutes of Health
  3. Japanese Initiative for Progress of Research on Infectious Disease for Global Epidemics Japan Agency for Medical Research and Development [JP17fm0208101]
  4. Japan Society for the Promotion of Science
  5. Grants-in-Aid for Scientific Research [16H02627, 16J04404, 15H01249] Funding Source: KAKEN

Ask authors/readers for more resources

Niemann-Pick C1 (NPC1), a host receptor involved in the envelope glycoprotein (GP)-mediated entry of filoviruses into cells, is believed to be a major determinant of cell susceptibility to filovirus infection. It is known that proteolytically digested Ebola virus (EBOV) GP interacts with 2 protruding loops in domain C of NPC1. Using previously published structural data and the National Center for Biotechnology Information Single-Nucleotide Polymorphism (SNP) database, we identified 10 naturally occurring missense SNPs in human NPC1. To investigate whether these SNPs affect cell susceptibility to filovirus infection, we generated Vero E6 cell lines stably expressing NPC1 with SNP substitutions and compared their susceptibility to vesicular stomatitis virus pseudotyped with filovirus GPs and infectious EBOV. We found that some of the substitutions resulted in reduced susceptibility to filoviruses, as indicated by the lower titers and smaller plaque/focus sizes of the viruses. Our data suggest that human NPC1 SNPs may likely affect host susceptibility to filoviruses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Microbiology

Advances and gaps in SARS-CoV-2 infection models

Cesar Munoz-Fontela, Lina Widerspick, Randy A. Albrecht, Martin Beer, Miles W. Carroll, Emmie de Wit, Michael S. Diamond, William E. Dowling, Simon G. P. Funnell, Adolfo Garcia-Sastre, Nora M. Gerhards, Rineke de Jong, Vincent J. Munster, Johan Neyts, Stanley Perlman, Douglas S. Reed, Juergen A. Richt, Ximena Riveros-Balta, Chad J. Roy, Francisco J. Salguero, Michael Schotsaert, Lauren M. Schwartz, Robert A. Seder, Joaquim Segales, Seshadri S. Vasan, Ana Maria Henao-Restrepo, Dan H. Barouch

Summary: Animal models play a crucial role in evaluating the virulence, transmission, and immune escape of SARS-CoV-2 variants and are continuously being improved to better replicate the demographic characteristics of COVID-19.

PLOS PATHOGENS (2022)

Article Microbiology

Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo

Julia R. Port, Claude Kwe Yinda, Victoria A. Avanzato, Jonathan E. Schulz, Myndi G. Holbrook, Neeltje van Doremalen, Carl Shaia, Robert J. Fischer, Vincent J. Munster

Summary: The major transmission route for SARS-CoV-2 is airborne. Experimental evidence shows that the Alpha variant has a higher competition advantage in airborne transmission compared to lineage A.

NATURE MICROBIOLOGY (2022)

Article Multidisciplinary Sciences

SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated rhesus macaques as compared to Delta

Neeltje van Doremalen, Manmeet Singh, Taylor A. Saturday, Claude Kwe Yinda, Lizzette Perez-Perez, W. Forrest Bohler, Zachary A. Weishampel, Matthew Lewis, Jonathan E. Schulz, Brandi N. Williamson, Kimberly Meade-White, Shane Gallogly, Atsushi Okumura, Friederike Feldmann, Jamie Lovaglio, Patrick W. Hanley, Carl Shaia, Heinz Feldmann, Emmie de Wit, Vincent J. Munster, Kyle Rosenke

Summary: In rhesus macaque model, disease severity and viral loads were lower in those inoculated with Omicron VOC compared to Delta VOC, suggesting reduced clinical disease caused by Omicron.

SCIENCE ADVANCES (2022)

Article Infectious Diseases

Dr Heinz Feldmann, Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy an

Andrea Marzi, Paige Fletcher, Friederike Feldmann, Greg Saturday, Patrick W. Hanley, Heinz Feldmann

Summary: This study aimed to develop an emergency vaccine against Sudan virus (SUDV) outbreaks. The results showed that the Sudan virus-specific vaccine effectively protected non-human primates from lethal SUDV infection. Additionally, previous vaccination with the Ebola virus vaccine had little cross-protective effect against SUDV challenge.

LANCET MICROBE (2023)

Article Pathology

Histopathology and SARS-CoV-2 Cellular Localization in Eye Tissues of COVID-19 Autopsies

H. Nida Sen, Kevin M. Vannella, Yujuan Wang, Joon-Yong Chung, Shilpa Kodati, Sabrina C. Ramelli, Jung Wha Lee, Paola Perez, Sydney R. Stein, Alison Grazioli, James M. Dickey, Kris Ylaya, Manmeet Singh, Kwe Claude Yinda, Andrew Platt, Marcos J. Ramos-Benitez, Christa Zerbe, Vincent J. Munster, Emmie de Wit, Blake M. Warner, Daniel L. Herr, Joseph Rabin, Kapil K. Saharia, David E. Kleiner, Stephen M. Hewitt, Chi-Chao Chan, Daniel S. Chertowt

Summary: This study evaluated the pathology and cellular localization of SARS-CoV-2 in ocular tissues through autopsy. It found histopathologic abnormalities in ocular tissues and identified the localization of SARS-CoV-2 RNA in multiple cell types. Further studies are needed to determine the cause of these alterations.

AMERICAN JOURNAL OF PATHOLOGY (2023)

Editorial Material Immunology

Marburg Virus Disease: Global Threat or Isolated Events?

Andrea Marzi, Heinz Feldmann

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Immunology

The roles of XJ13 and XJ44-specific mutations within the Candid #1 GPC in Junin virus attenuation

John Tyler Manning, Junki Maruyama, Timothy Wanninger, Rachel A. Reyna, Heather L. Stevenson, Bi-Hung Peng, Emily K. Mantlo, Cheng Huang, Slobodan Paessler

Summary: Junin virus, the cause of Argentine hemorrhagic fever, can be attenuated through specific mutations in the glycoprotein precursor gene. Early mutations attenuate the visceral disease and enhance immunogenicity in guinea pigs, while a specific mutation within an N-linked glycosylation motif is necessary for complete attenuation and enhanced immunogenicity of the Candid#1 vaccine strain.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, General & Internal

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine

Kyle L. O'Donnell, Friederike Feldmann, Benjamin Kaza, Chad S. Clancy, Patrick W. Hanley, Paige Fletcher, Andrea Marzi

Summary: Marburg virus (MARV) is a highly pathogenic agent with no available treatments or vaccines. This study demonstrates that a vesicular stomatitis virus (VSV)-based vaccine expressing the MARV-Angola glycoprotein has a potential as a viable and fast-acting MARV vaccine candidate, providing uniform protection against the virus when administered in lower doses.

EBIOMEDICINE (2023)

Editorial Material Medicine, General & Internal

Multidimensional sample analysis to determine pandemic viral evolution

Kyle L. O'Donnell, Andrea Marzi

EBIOMEDICINE (2023)

Review Immunology

Vaccine Candidates against Arenavirus Infections

Takeshi Saito, Rachel A. A. Reyna, Satoshi Taniguchi, Kirsten Littlefield, Slobodan Paessler, Junki Maruyama

Summary: The Arenaviridae family includes viruses that cause severe and often fatal diseases in humans. High-containment facilities are required to handle these highly pathogenic viruses. The development of vaccines is essential for combating arenavirus infections, but currently there are limited options available. We provide a summary of the recent updates on vaccine candidates against these viruses.

VACCINES (2023)

Article Virology

Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus

Miyuki Kimura, Risa Matsuoka, Satoshi Taniguchi, Junki Maruyama, Slobodan Paessler, Saori Oka, Atsushi Yamashita, Takasuke Fukuhara, Yoshiharu Matsuura, Hideki Tani

Summary: Through screening drug libraries, CB1 antagonists were found to effectively inhibit the entry of Lujo virus into cells and reduce infectivity. These findings provide promising candidate drugs for the treatment of Lujo virus infections.

VIROLOGY (2023)

Article Multidisciplinary Sciences

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters

Julia R. Port, Claude Kwe Yinda, Jade C. Riopelle, Zachary A. Weishampel, Taylor A. Saturday, Victoria A. Avanzato, Jonathan E. Schulz, Myndi G. Holbrook, Kent Barbian, Rose Perry-Gottschalk, Elaine Haddock, Craig Martens, Carl. I. Shaia, Teresa Lambe, Sarah C. Gilbert, Neeltje van Doremalen, Vincent J. Munster

Summary: Limited data is available on the effect of vaccination and previous virus exposure on the nature of SARS-CoV-2 transmission and immune-pressure on variants. A study found that transmission efficacy was reduced by approximately 60% in hamsters vaccinated via the intramuscular route and by 80% in previously infected hamsters and those vaccinated via the intranasal route. Additionally, the Omicron B.1.1.529 variant showed increased competitiveness in groups with pre-existing immunity against the Delta B.1.617.2 variant. These findings highlight the importance of improving vaccination strategies.

NATURE COMMUNICATIONS (2023)

Article Immunology

Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus

Cecilia A. Prator, Brianna M. Dorratt, Kyle L. O'Donnell, Justin Lack, Amanda N. Pinski, Stacy Ricklefs, Craig A. Martens, Ilhem Messaoudi, Andrea Marzi

Summary: This study found that infection with Marburg virus causes a highly fatal disease in humans, with no currently available vaccines or therapeutics. However, a low dose of the VSV-MARV vaccine has shown promise in protecting nonhuman primates from the disease. This suggests that the low dose VSV-MARV vaccine could be a beneficial option in public health efforts during future outbreaks.

EMERGING MICROBES & INFECTIONS (2023)

Article Multidisciplinary Sciences

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

Mackenzie Zendt, Fausto A. Bustos Carrillo, Sophie Kelly, Taylor Saturday, Maureen Degrange, Anita Ginigeme, Lurline Wu, Viviane Callier, Ana Ortega-Villa, Mondreakest Faust, Emma Chang-Rabley, Kara Bugal, Heather Kenney, Pavel Khil, Jung-Ho Youn, Gloria Osei, Pravesh Regmi, Victoria Anderson, Marita Bosticardo, Janine Daub, Thomas Dimaggio, Samantha Kreuzburg, Francesca Pala, Justina Pfister, Jennifer Treat, Jean Ulrick, Maria Karkanitsa, Heather Kalish, Douglas B. Kuhns, Debra L. Priel, Danielle L. Fink, John S. Tsang, Rachel Sparks, Gulbu Uzel, Meryl A. Waldman, Christa S. Zerbe, Ottavia M. Delmonte, Jenna R. E. Bergerson, Sanchita Das, Alexandra F. Freeman, Michail S. Lionakis, Kaitlyn Sadtler, Neeltje van Doremalen, Vincent Munster, Luigi D. Notarangelo, Steven M. Holland, Emily E. Ricotta

Summary: Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people has primarily focused on cancer and organ transplantation populations. Three doses of the vaccine induced antispike IgG in most immune-deficient/disordered individuals, but additional doses are required for increased protection. The reduced IgG response to the Omicron BA.1 variant highlights the need for studying the efficacy of additional vaccinations, including bivalent vaccines, in this population.

SCIENCE ADVANCES (2023)

Article Multidisciplinary Sciences

Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates

Bharti Bhatia, Tsing-Lee Tang-Huau, Friederike Feldmann, Patrick W. Hanley, Rebecca Rosenke, Carl Shaia, Andrea Marzi, Heinz Feldmann

Summary: This study demonstrates the efficacy of a VSV-based vaccine in providing protection against KFDV and related diseases, and inducing cross-reactive immune responses.

SCIENCE ADVANCES (2023)

No Data Available